Visible-light Optical Coherence Tomography (vis-OCT)
Optical coherence tomography (OCT) has transformed clinical eye care, ocular drug development, and fundamental ophthalmology and vision research since it was reported in 1991. Visible-light optical coherence tomography (vis-OCT) is the latest development of OCT technology, providing new capabilities in both anatomical and functional imaging of biological tissue. It relies on visible light illumination, whereas most commercial and investigational OCTs use near-infrared light. As a result, vis-OCT requires different considerations in engineering design and implementation but brings unique benefits to both fundamental research and clinical care of leading blinding diseases. Vis-OCT was first reported by Prof. Hao F. Zhang's group at Northwestern University in 2013 in small animals and, in 2015, the Zhang lab further demonstrated the first vis-OCT imaging of human retinas. Opticent Health is focusing on two vis-OCT products, Aurora X4 for humans and Halo 375 for small animals, after numerous technical iterations and improvements since 2017. For more details, please refer to our products page and milestone papers.
​
​
New functional imaging of the retinal physiology
Thanks to the much improved optical contract in the visible-light spectral range, our technology offers new functional analyses of the eye like no other.
Highest-resolution retinal imaging
Our technology offers 1.3 micrometer axial resolution in human eye, nearly three-times higher than the state-of-the-art clinical OCTs.
Revolutionary small-animal ocular imaging capabilities
Best functional and anatomical imaging of both anterior and posterior segments of small animal eyes.